Haisco plans to provide up to 261 million yuan in financial assistance to controlling subsidiary Haisco Geneo

Jiemian··CN·Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Haisco Pharmaceutical Group announced it plans to use its own funds to provide a loan of up to 261 million yuan to its controlling subsidiary, Shanghai Haisco Geneo Biotechnology, for research and development investment and working capital turnover. The loan carries an annual interest rate of 3.05 percent and a term of five years. Haisco Geneo was established in March 2026, with the company holding an 86.69 percent stake, focusing on cutting-edge areas such as ADC and In Vivo CART. Minority shareholder Helix will provide financial assistance of up to 30 million yuan on the same terms in proportion to its capital contribution. As of the announcement date, the company's total outstanding financial assistance balance is 261 million yuan, accounting for 6.09 percent of net assets, with no overdue unrecovered amounts.

Impact on assets 1

Others▲ · 1 stocks

Off-coverage companies 2

Shanghai Haisijino Biotechnology Co., Ltd.Private▲ Positive
Capitalrelevance

Receives up to 261 million yuan loan for R&D and working capital.

Helix (Chengdu) Pharmaceutical Technology Co., Ltd.Private▲ Positive
Capitalrelevance

Provides proportional financial assistance of up to 30 million yuan to subsidiary.

© 2026 MarketIVNews